LAUSR

Introduction/Background Progress in early diagnosis, treatment efficacy have allowed increased life expectancy in cancer patients (1). Therefore, approximately 6% childbearing age individuals are cancer survivors (2). In this specific setting, 20% of malignant epithelial ovarian tumours (MEOT) are diagnosed before the age of 44, with a 91.2% five years survival rate for stage IA and IB (3). Similarly rare malignant ovarian tumors (RMOT) and borderline ovarian tumours (BOT) more frequently occur in women of childbearing age (4). Personalized counseling on post treatment ovarian function and possibilities of fertility preservation (FP) are part of oncological patients‘ care (5). However the safety and efficiency evidence level is currently too limited to allow specific recommendations. Therefore, we report the experience in FP for patients with malignant ovarian tumours, at a French ESGO labeled national expert center and pregnancy-associated cancer network (CALG). Methodology Data from 43 patients with malignant ovarian tumors who underwent a FP between February 2013 and July 2019 were analysed from the prospective unicentric database. Results Pathological diagnosis was 5 (11.6%) MEOT, 14 (32.6%) RMOT, 24 (55.8%) BOT, mostly unilateral (76.5%) and stage I (87.9%). Mean age at diagnosis and tumor size was 26.8 and 97.4 mm respectively. Before fertility preservation, mean antral follicle count and AMH levels were 9 [0–20], and 2.26 ng/ml [0.1–10]. Mean age at fertility preservation was 29.2 [17.4–37.1]. Six ovarian tissue freezing procedures were performed out of 14 proposed. 23 oocyte freezing procedures were performed after tumor surgical treatment out of 26 proposed, with a median delay of 188 days. The mean mature oocytes collected number was 12.9. No FP was proposed for 5 patients. Conclusion Oocyte and ovarian tissue cryopreservation can be offered to patients with malignant ovarian tumor. More data are needed to confirm ovarian stimulation and ovarian tissue grafting safety. Disclosure Nothing to disclose Abstract EP1273 Table 1 Population caracteristics Histology [n] Maligant epithelial ovarian tumor [n=5] Rare malignant ovarian tumor [n=14] Borderline ovarian tumor [n=24] All tumors [n=43] Age at diagnosis (mean, years) 29.4 (24–36) [n=5] 24.9 (9–35) [n=14] 27.4 (17–39) [n=24] 26.8 (9–39)[n=43] BMI (mean, kg/m²) 23.5 (19–29.7) [n=4] 21.8 (18.1–32) [n=13] 24.7 (17.8–43.4) [n=22] 24.2 (17.8–43.4) [n=38] Parity (%) 25 [n=4] 15.4 [n=13] 4.2 [n=24] 9.8 [n=41] Smoking (%) 0 [n=4] 18.2 [n=11] 42.9 [n=21] 30.6 [n=36] Fertility preservation consultation preoperative (%) 20 [n=5] 23.1 [n=13] 29.2 [n=24] 26.2 [n=42] AFC before multidisciplinary committee (mean) 10.5 (8–13) [n=2] 9.25 (2–20)[n=12] 12.7 (3–30) [n=12] 11 (2–30) [n=26] AMH before multidisciplinary committee (mean, ng/ml) 1.3 (0.7–2) [n=2] 1.8 (0.03–4.26) [n=9] 3.4 (0–23) [n=16] 2.7 (0–23) [n=27] Bilateral lesions (%) 66.7 [n=3] 22 [n=9] 18.2 [n=22] 23.6 [n=34] Ovarian tumor size to imaging (mean, mm) 68.9 (20–155) [n=5] 84.1 (7–260 [n=17] 91.8 (18–240) [n=26] 96.8 (7–260) [n=48] Abstract EP1273 Table 2 Fertility preservation results Histology [n] Malignant epithelial ovarian tumor [n=5] Rare malignant ovarian tumor [n=14] Borderline ovarian tumor [n=24] All tumors [n=43] Ovarian tissu freezing realised/proposed 0/1 2/4 4/9 6/14 Fragment number NA 11 [n=1] 27.4 (16–30) [n=3] 17 (1–30) [n=5] Fragments follicular density (mean, primordial follicles/mm²) NA 0.08 (0–0.16) [n=2] 0.045 (0.02–0.07) [n=2] 0.06 (0–0.16) [n=4] Mature oocytes freezing realised/proposed 3/3 6/8 9/16 18/27 Average time after surgery (mean, days) 429 (34–1446) [n=4] 2232 (61–8348) [n=6] 298 (46–643) [n=13] 824 (34–8348) [n=23] Total gonadotrophine dose (mean, IU) 2450 (1200–4050) [n=3] 4083 (2750–5850) [n=6] 3521 (950–6300) [n=13] 3528 (950–6300) [n=22] Stimulation duration (mean, days) 8 (6–11) [n=3] 11.6 (8–15) [n=6] 11.1 (10–14) [n=13] 10.8 (6–15) [n=22] Expected oocytes number (mean) 10 (3–17) [n=2] 11.8 (0–33) [n=6] 14.2 (6–29) [n=13] 13.1 (0–33) [n=21] Mature oocytes number (mean) 7 (1–18) [n=3] 14.8 (6–29) [n=5] 13.6 (3–58) [n=13] 13 (3–58) [n=21]